Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib with Abiraterone and Prednisone for mCRPC
NCT01848067Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2013; status: completed.
02
Drugs
alisertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01848067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01848067.